Upfront treatment with Hemlibra (emicizumab-KXWH) may help reduce hospitalization costs associated with treating bleeds in older adults with acquired hemophilia A (AHA), according to a study. While Hemlibra itself carries a hefty price tag, economic models indicate that using the therapy may help shorten hospital stays and reduce…
News
Switching clotting factor products did not cause new inhibitors (neutralizing antibodies that can prevent the treatment from working) to develop in previously treated patients with moderate or severe hemophilia A or B who had no detectable inhibitors at the time of switching. That’s according to data from ATHN…
Children with hemophilia who underwent surgery to remove the tonsils or adenoids experienced almost no bleeding complications when surgeons followed a structured bleeding management plan, according to a 14-year single medical center review. Of 18 pediatric hemophilia patients who underwent the surgery, one child had a minor bleeding episode,…
While patient-reported measures can provide valuable insight into an individual’s experience with hemophilia, a study suggests they may not be reliable for comparing outcomes across different hospitals. “Patient-centered outcomes demonstrate low to moderate reliability for hospital-level comparisons,” researchers wrote in the paper, “Assessing the Real-World Value of Hemophilia…
Women and girls with hemophilia continue to face delayed diagnoses, unequal access to treatment, and underrepresentation in clinical trials, even though many experience significant bleeding, according to a new analysis. Researchers described these interconnected problems as the “XX gap” in hemophilia care. Closing this gap, they said, requires moving…
Long-term treatment with Hemlibra (emicizumab) provided sustained protection against bleeding for up to five years in people with hemophilia A, with no new safety concerns identified, according to a large real-world study from Canada. The study, which analyzed data from 710 people with hemophilia A, found that more…
Recognizing acquired hemophilia A (AHA) early and ordering simple blood clotting tests in older patients with unexplained bruising or anemia — a low number of red blood cells — may help shorten diagnostic delays, according to a Singapore study in which the median time to diagnosis was four days,…
Once-weekly infusions of Altuvoct (efanesoctocog alfa) — a long-lasting hemophilia treatment marketed in the U.S. as Altuviiio — reduced bleeding in adults and children with hemophilia A for whom preventive treatment was not sufficiently effective. That’s the key finding of a new French real-world study that tracked…
Children’s Hospital of Philadelphia (CHOP) has been awarded up to $38.9 million to advance the development of personalized gene‑editing therapies for four groups of rare genetic disorders — one of them hemophilia. The five-year award comes from the Advanced Research Projects Agency for Health (ARPA‑H) under its…
Although it’s often mistakenly thought of as a male disease, hemophilia affects a substantial number of women and girls, manifesting with symptoms that can include heavy menstrual periods and mental health challenges. That’s according to a new review paper that examined “each stage of the process” for female patients…
